Immunohistochemical and Genomic Evidence for the Expression of Somatostatin Receptors 1-5 and Dopamine Receptor 2 in Lung Carcinoids Abstract #819

Introduction: Expression of somatostatin receptors (SSTRs) and dopamine receptor 2 (DR2) in neuroendocrine tumors is of clinical importance, as they represent potential targets for diagnosis and treatment.
Aim(s): To examine the expression of the five SSTR subtypes and DR2 subtype in lung carcinoids (LCs) by means of immunohistochemistry (IHC) and real time polymerase chain reaction (RT-PCR)
Materials and methods: A retrospective study of 119 LCs from 106 patients [typical carcinoids (TCs) n=100, and atypical carcinoids (ACs) n=19] was conducted. The expression of all five SSTR subtypes and DR2 was evaluated by IHC and correlated to clinocopathological data. In a subgroup of cases, receptor expression was further analyzed using RT-PCR. SSTR expression was also correlated to Octreoscan data.
Conference: 11th Annual ENETS Conference (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: George A Kanakis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#245 Expression of Somatostatin Receptors and Dopamine 2 Receptor in Lung Carcinoids as a Possible Biotherapy Target
Introduction: Expression of somatostatin receptors (SSTRs) and dopamine 2 receptor (D2R) in neuroendocrine tumors is of clinical importance, as somatostatin analogues and dopamine agonists are used in biotherapy.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Apostolos V. Tsolakis
#313 Effect of Somatostatin Analogues in the Control of Tumor Growth in Patients with Metastatic Lung Carcinoid Tumors
Introduction: Antitumor effect of Somatostatin analogues has been poorly documented in metastatic typical or atypical lung carcinoid tumors (LCT).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Joël Guigay
#675 Olfactory Receptor 51E1 is a Potential Novel Target for Diagnosis and Treatment of Somatostatin Receptor Negative Lung Carcinoid Patients
Introduction: Somatostatin receptor (SSTR) expression may be used for diagnosis and therapy of lung carcinoids. However, novel targets are requested.
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Tao Cui
#911 Immunohistochemical Expression of Connective Tissue Growth Factor and Insulin-like Growth Factor-1 in Lung Carcinoids
Introduction: Several studies have shown altered expression of Insulin-like Growth Factor-1 (IGF-1) and its receptor (IGF-1R) in different types of cancers. Connective Tissue Growth Factor (CTGF) is triggered by Serotonin (5-HT) and Hypoxia Induced Factor 1 (HIF-1) and has been associated with tumor expansion and desmoplastic reaction in carcinoid tumors.
Conference: 11th Annual ENETS Conference (2014)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: George A Kanakis
Keywords: lung, carcinoid, CTGF, IGF-1
#1938 Eleven Years Survival after Combined Treatment of Surgery, Ultrasound-Guided Radiofrequency Ablation of Liver Metastasis, CT Embolization Plus Somatostatin LAR in a Case with Atypical Carcinoid of the Lung
Introduction: The combination of different therapeutic methods has an important place in the treatment of patients with NET and liver metastasis, ineligible for radical surgery.
Conference: 14th Annual ENETS conference (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Prof. Borislav Vladimirov